Cysteinyl leukotriene receptor 1/2 antagonists nonselectively modulate organic anion transport by multidrug resistance proteins (MRP1-4)s

Drug Metabolism and Disposition

Volumn 44, Issue 6, 2016, Pages 857-866

  Csandl, Mark A ^a   Conseil, Gwenaëlle ^a   Cole, Susan P C ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[(3 CARBOXYCYCLOHEXYL)AMINO]CARBONYL] 4 [3 [4 (4 PHENOXYBUTOXY)PHENYL]PROPOXY]BENZOIC ACID; 3 [[(3 CARBOXYCYCLOHEXYL)AMINO]CARBONYL] 4 [3 [4 [4 (CYCLOHEXYLOXY)BUTOXY]PHENYL]PROPOXY]BENZOIC ACID; 6 (4 CARBOXYPHENYLTHIO) 5 HYDROXY 7,9,11,14 ICOSATETRAENOIC ACID; ESTRADIOL 17 GLUCURONIDE; LEUKOTRIENE C4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; PRANLUKAST; PROSTAGLANDIN E2; TOMELUKAST; UNCLASSIFIED DRUG; VERLUKAST; ABC TRANSPORTER SUBFAMILY B; CYSTEINYL LEUKOTRIENE RECEPTOR 2; ESTRADIOL; ESTRADIOL-17 BETA-GLUCURONIDE; LEUKOTRIENE D4 RECEPTOR; LEUKOTRIENE RECEPTOR; ORGANIC ANION TRANSPORTER; PROPIONIC ACID DERIVATIVE; QUINOLINE DERIVATIVE;

ANION TRANSPORT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC50; MEMBRANE VESICLE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CELL LINE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY B; BIOLOGICAL TRANSPORT; CELL LINE; ESTRADIOL; HEK293 CELLS; HUMANS; ORGANIC ANION TRANSPORTERS; PROPIONATES; QUINOLINES; RECEPTORS, LEUKOTRIENE;

EID: 84965014212     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.116.069468     Document Type: Article

References (57)

1. Bakos E, Evers R, Sinkó E, Váradi A, Borst P, and Sarkadi B (2000) Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 57: 760-768.
2. Barrington RD, Needs PW, Williamson G, and Kroon PA (2015) MK571 inhibits phase-2 conjugation of flavonols by Caco-2/TC7 cells, but does not specifically inhibit their apical efflux. Biochem Pharmacol 95:193-200.
3. Bodo A, Bakos E, Szeri F, Varadi A, and Sarkadi B (2003) Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem 278: 23529-23537.
4. Boumendjel A, Baubichon-Cortay H, Trompier D, Perrotton T, and Di Pietro A (2005) Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med Res Rev 25:453-472.
5. Cheung L, Flemming CL, Watt F, Masada N, Yu DMT, Huynh T, Conseil G, Tivnan A, Polinsky A, and Gudkov AV, et al. (2014) High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). Biochem Pharmacol 91:97-108.
6. Chu X-Y, Huskey S-EW, Braun MP, Sarkadi B, Evans DC, and Evers R (2004) Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. J Pharmacol Exp Ther 309:156-164.
7. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, and Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910.
8. Cole SPC (2014a) Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol 54:95-117.
9. Cole SPC (2014b) Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter. J Biol Chem 289:30880-30888.
10. Conseil G and Cole SPC (2013) Two polymorphic variants of ABCC1 selectively alter drug resistance and inhibitor sensitivity of the multidrug and organic anion transporter multidrug resistance protein 1. Drug Metab Dispos 41:2187-2196.
11. Dantzig AH, Shepard RL, Pratt SE, Tabas LB, Lander PA, Ma L, Paul DC, Williams DC, Peng S-B, and Slapak CA, et al. (2004) Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATPbinding cassette (ABC) drug transporters. Biochem Pharmacol 67:1111-1121.
12. Diamant Z, Mantzouranis E, and Bjermer L (2009) Montelukast in the treatment of asthma and beyond. Expert Rev Clin Immunol 5:639-658.
13. Fleisch JH, Rinkema LE, Haisch KD, Swanson-Bean D, Goodson T, Ho PPK, and Marshall WS (1985) LY171883, 1-,2-hydroxy-3-propyl-4-,4-(1H-tetrazol-5-yl) butoxy.phenyl.ethanone, an orally active leukotriene D4 antagonist. J Pharmacol Exp Ther 233:148-157.
14. Foxworthy PS, Perry DN, Hoover DM, and Eacho PI (1990) Changes in hepatic lipid metabolism associated with lipid accumulation and its reversal in rats given the peroxisome proliferator LY171883. Toxicol Appl Pharmacol 106:375-383.
15. Gekeler V, Ise W, Sanders KH, Ulrich WR, and Beck J (1995) The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 208:345-352.
16. Gerk PM, Li W, and Vore M (2004) Estradiol 3-glucuronide is transported by the multidrug resistance-associated protein 2 but does not activate the allosteric site bound by estradiol 17-glucuronide. Drug Metab Dispos 32:1139-1145.
17. Haeggström JZ and Funk CD (2011) Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev 111:5866-5898.
18. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille JN, Abramovitz M, and Cheng R, et al. (2000) Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275:30531-30536.
19. Hipfner DR, Gauldie SD, Deeley RG, and Cole SPC (1994) Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 54:5788-5792.
20. Ibarra-Barrueta O, Palacios-Zabalza I, Mora-Atorrasagasti O, and Mayo-Suarez J (2014) Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events. Ann Pharmacother 48:145-148.
21. Ito K, Oleschuk CJ, Westlake C, Vasa MZ, Deeley RG, and Cole SPC (2001) Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J Biol Chem 276: 38108-38114.
22. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, and Keppler D (1996) Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56:988-994.
23. Jin D, Ni TT, Sun J, Wan H, Amack JD, Yu G, Fleming J, Chiang C, Li W, and Papierniak A, et al. (2014) Prostaglandin signalling regulates ciliogenesis by modulating intraflagellar transport. Nat Cell Biol 16:841-851.
24. Jones TR, Zamboni R, Belley M, Champion E, Charette L, Ford-Hutchinson AW, Frenette R, Gauthier JY, Leger S, and Masson P, et al. (1989) Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 67: 17-28.
25. Kartenbeck J, Leuschner U, Mayer R, and Keppler D (1996) Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 23:1061-1066.
26. Keam SJ, Lyseng-Williamson KA, and Goa KL (2003) Pranlukast: a review of its use in the management of asthma. Drugs 63:991-1019.
27. Keppler D (2011) Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handbook Exp Pharmacol 201:299-323.
28. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, and Scheper RJ, et al. (1999) MRP3, an organic anion transporter able to transport anticancer drugs. Proc Natl Acad Sci USA 96:6914-6919.
29. Létourneau IJ, Slot AJ, Deeley RG, and Cole SPC (2007) Mutational analysis of a highly conserved proline residue in MRP1, MRP2, and MRP3 reveals a partially conserved function. Drug Metab Dispos 35:1372-1379.
30. Letschert K, Komatsu M, Hummel-Eisenbeiss J, and Keppler D (2005) Vectorial transport of the peptide CCK-8 by double-transfected MDCKII cells stably expressing the organic anion transporter OATP1B3 (OATP8) and the export pump ABCC2. J Pharmacol Exp Ther 313: 549-556.
31. Lin ZP, Zhu YL, Johnson DR, Rice KP, Nottoli T, Hains BC, McGrath J, Waxman SG, and Sartorelli AC (2008) Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response. Mol Pharmacol 73:243-251.
32. Loe DW, Almquist KC, Deeley RG, and Cole SPC (1996) Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 271: 9675-9682.
33. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, and Zeng Z, et al. (1999) Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399:789-793.
34. Matsson P, Pedersen JM, Norinder U, Bergström CAS, and Artursson P (2009) Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26:1816-1831.
35. Myette RL, Conseil G, Ebert SP, Wetzel B, Detty MR, and Cole SPC (2013) Chalcogenopyrylium dyes as differential modulators of organic anion transport by multidrug resistance protein 1 (MRP1), MRP2, and MRP4. Drug Metab Dispos 41:1231-1239.
36. Nagayama S, Chen ZS, Kitazono M, Takebayashi Y, Niwa K, Yamada K, Tani A, Haraguchi M, Sumizawa T, and Furukawa T, et al. (1998) Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO-1078. Cancer Lett 130:175-182.
37. Ni NC, Yan D, Ballantyne LL, Barajas-Espinosa A, St Amand T, Pratt DA, and Funk CD (2011) A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice. JPharmacolExpTher339:768-778.
38. Nies AT and Keppler D (2007) The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 453:643-659.
39. Nothacker HP, Wang Z, Zhu Y, Reinscheid RK, Lin SH, and Civelli O (2000) Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol 58:1601-1608.
40. Oleschuk CJ, Deeley RG, and Cole SPC (2003) Substitution of Trp1242 of TM17 alters substrate specificity of human multidrug resistance protein 3. Am J Physiol Gastrointest Liver Physiol 284: G280-G289.
41. Park J, Kwak JO, Riederer B, Seidler U, Cole SP, Lee HJ, and Lee MG (2014) Na+/H+ exchanger regulatory factor 3 is critical for multidrug resistance protein 4-mediated drug efflux in the kidney. JAmSocNephrol25:726-736.
42. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, and Borst P (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 100:9244-9249.
43. Sarau HM, Ames RS, Chambers J, Ellis C, Elshourbagy N, Foley JJ, Schmidt DB, Muccitelli RM, Jenkins O, and Murdock PR, et al. (1999) Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 56:657-663.
44. Schneider EK, Huang JX, Carbone V, Baker M, Azad MA, Cooper MA, Li J, and Velkov T (2015) Drug-drug plasma protein binding interactions of ivacaftor. JMolRecognit28:339-348.
45. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, and Fridland A (1999) MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5:1048-1051.
46. Slot AJ, Molinski SV, and Cole SPC (2011) Mammalian multidrug-resistance proteins (MRPs). Essays Biochem 50:179-207.
47. Tang SC, Hendrikx JJ, Beijnen JH, and Schinkel AH (2013) Genetically modified mouse models for oral drug absorption and disposition. Curr Opin Pharmacol 13:853-858.
48. Van Aubel RAMH, Smeets PHE, van den Heuvel JJMW, and Russel FGM (2005) Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 288:F327-F333.
49. van Brussel JP, Oomen MA, Vossebeld PJM, Wiemer EAC, Sonneveld P, and Mickisch GHJ (2004) Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine. BJU Int 93:1333-1338.
50. van der Schoor LW, Verkade HJ, Kuipers F, and Jonker JW (2015) New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition. Expert Opin Drug Metab Toxicol 11:273-293.
51. van de Wetering K, Zelcer N, Kuil A, Feddema W, Hillebrand M, Vlaming ML, Schinkel AH, Beijnen JH, and Borst P (2007) Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol Pharmacol 72:387-394.
52. Wijnholds J, Scheffer GL, van der Valk M, van der Valk P, Beijnen JH, Scheper RJ, and Borst P (1998) Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J Exp Med 188:797-808.
53. Wittgen HG, van den Heuvel JJ, van den Broek PH, Dinter-Heidorn H, Koenderink JB, and Russel FG (2011) Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-associated proteins MRP1, MRP2, MRP3, and MRP4. Drug Metab Dispos 39: 1294-1302.
54. Wittgen HGM, van den Heuvel JJMW, Krieger E, Schaftenaar G, Russel FGM, and Koenderink JB (2012) Phenylalanine 368 of multidrug resistance-associated protein 4 (MRP4/ABCC4) plays a crucial role in substrate-specific transport activity. Biochem Pharmacol 84:366-373.
55. Wunder F, Tinel H, Kast R, Geerts A, Becker EM, Kolkhof P, Hütter J, Ergüden J, and Härter M (2010) Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol 160:399-409.
56. Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P, Schellens JHM, Schinkel AH, and Borst P (2003) Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem 278:23538-23544.
57. Zhang XY, Wang XR, Xu DM, Yu SY, Shi QJ, Zhang LH, Chen L, Fang SH, Lu YB, and Zhang WP, et al. (2013) HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J Pharmacol Exp Ther 346:328-341.